ReviewNature reviews. Disease primers2016
Lyme borreliosis.
Review in Nature reviews. Disease primers, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 505 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
505 citing papers in PubMed, 1 synthesis or guideline pooled it, 821 citations in OpenAlex.
- Borrelia Infections Under B Cell-Depleting Therapies: A Systematic Review of Diagnostic Challenges and Outcomes With Special Focus on Neurological Forms.European journal of neurology · 2026Pooled it
- Serum neurofilament light chain associates with symptom burden in Lyme neuroborreliosis patients: a longitudinal cohort study from Norway.Journal of neurology · 2024Trial
- Curiouser and curiouser: understanding the intersection of inter- and intra-specific diversity during theInfection and immunity · 2026Review
- Powassan Virus in the United States: An AI-Integrative One Health Scoping Review of Ecological Drivers, Zoonotic Interactions, Symptom Profiles, and Public Health Implications.Infectious disease reports · 2026Review
- Dynamics of IgM and IgG responses in Lyme neuroborreliosis - a Norwegian longitudinal study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Antiphospholipid antibodies in acute and post-treatment Lyme disease.Infection and immunity · 2026Article
- Clinical Features and Outcomes of Pediatric Lyme Arthritis in Europe: A Large Swiss Cohort Study.Open forum infectious diseases · 2026Article
- Findings From Electronic Medical Record Review of 2500 Patients Identified With Lyme Disease Diagnoses, Test Orders, and Antibiotic Orders in the SubLyme Network.Open forum infectious diseases · 2026Article
- Bactofilins are essential spatial organizers of peptidoglycan insertion in the Lyme disease spirocheteJournal of bacteriology · 2026Article
- Prevalence and Associated Factors ofMicroorganisms · 2026Review
- A rare presentation of clinically diagnosed lyme disease with probable neuroborreliosis, septic shock, and bone marrow suppression: a case report.BMC infectious diseases · 2026Article
- Patient-Reported Health-Related Quality of Life Impact and Symptom Severity in Patients with Lyme Borreliosis in the Burden of Lyme Disease (BOLD) Study.Pathogens (Basel, Switzerland) · 2026Article
- Article
- Glycolytic reprogramming in host response toExperimental and therapeutic medicine · 2026Article
- Structural basis for selective thymidine binding by the Borrelia burgdorferi substrate-binding protein BmpA.The Journal of biological chemistry · 2026Article
- The Journey of Adult Patients with Lyme Disease in the United States: A Qualitative Interview Study and Patient-Reported, Health-Related Quality-of-Life Assessment.Advances in therapy · 2026Article
- Anti-Pathogens (Basel, Switzerland) · 2026Article
- Characterization of Anti-Phospholipid Antibodies in Lyme Borreliosis Using In-House Developed ELISAs.Antibodies (Basel, Switzerland) · 2026Article
- Evaluation of EcoCRM, virus-like particles, and mRNA as vaccine platforms against Borrelia burgdorferi.Vaccine · 2026Article
- Fast and efficient Borrelia chromosome recovery from tick samples using whole-genome amplification.Cell reports methods · 2026Article
445 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 7 institutions in 3 countries.
Funding
Abstract
Lyme borreliosis is a tick-borne disease that predominantly occurs in temperate regions of the northern hemisphere and is primarily caused by the bacterium Borrelia burgdorferi in North America and Borrelia afzelii or Borrelia garinii in Europe and Asia. Infection usually begins with an expanding skin lesion, known as erythema migrans (referred to as stage 1), which, if untreated, can be followed by early disseminated infection, particularly neurological abnormalities (stage 2), and by late infection, especially arthritis in North America or acrodermatitis chronica atrophicans in Europe (stage 3). However, the disease can present with any of these manifestations. During infection, the bacteria migrate through the host tissues, adhere to certain cells and can evade immune clearance. Yet, these organisms are eventually killed by both innate and adaptive immune responses and most inflammatory manifestations of the infection resolve. Except for patients with erythema migrans, Lyme borreliosis is diagnosed based on a characteristic clinical constellation of signs and symptoms with serological confirmation of infection. All manifestations of the infection can usually be treated with appropriate antibiotic regimens, but the disease can be followed by post-infectious sequelae in some patients. Prevention of Lyme borreliosis primarily involves the avoidance of tick bites by personal protective measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.